Author/Authors :
Carolina Urquiola، نويسنده , , Marisol Vieites، نويسنده , , Gabriela Aguirre، نويسنده , , Adoraci?n Mar?n، نويسنده , , Beatriz Solano، نويسنده , , Gabriel Arrambide، نويسنده , , Pabla Nobl?a، نويسنده , , Mar?a Laura Lavaggi، نويسنده , , Mar?a H. Torre، نويسنده , , Mercedes Gonzalez-Wangüemert، نويسنده , , Antonio Monge، نويسنده , , Dinorah Gambino، نويسنده , , Hugo Cerecetto، نويسنده ,
Abstract :
New vanadium complexes of the type [VIVO(L)2], where L are 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives, were prepared as an effort to obtain new anti-trypanosomal agents improving the bioactivity of the free ligands. Complexation to vanadium of the quinoxaline ligands leads to excellent antiprotozoal activity, similar to that of the reference drugs nifurtimox and benznidazole and in all cases higher than that of the corresponding free ligands. In addition, it is for the first time that the V(IV)O–quinoxaline complexes are reported as a family of anti-Trypanosoma cruzi agents. Finally, the anti-trypanosomal activity of these vanadium complexes could be explained on the basis of their lipophilicity and the electronic characteristics of the quinoxaline substituents.
Keywords :
Anti-trypanosomal activity , Quinoxaline N1 , N4-Dioxide , N , O Ligands , Vanadium
